Medicortex Finland Oy, a biotechnology company developing diagnostic tests for brain injury, announces successful closing of a pre-IPO share issue round that will allow the company to proceed to the next phase in the process of Initial Public Offering (IPO), in parallel to the development of its lead product candidate.

Medicortex Finland Oy (www.medicortex.fi) is a biotechnology company dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Company’s current focus is to develop biomarker diagnostics to evaluate mild TBI and concussion. The next goal of the company will be to develop an innovative drug to prevent the propagation and aggravation of traumatic brain injury from its initial local presence to a spread and more severe injury.

http://www.medicortex.fi/

Medicortex Closes Successful Pre-Ipo Funding Round

Medicortex Closes Successful Pre-Ipo Funding Round

Company Info